Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel. - Wikidata - wikimedia - TriplyDB

Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel.

Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel.

http://www.wikidata.org/entity/Q37080812

about

Multifunctional-autoprocessing repeats-in-toxin (MARTX) Toxins of Vibrios Vibrio vulnificus biotype 3 multifunctional autoprocessing RTX toxin is an adenylate cyclase toxin essential for virulence in mice Vibrio vulnificus: An Environmental and Clinical Burden Comparative genomic analysis of clinical and environmental Vibrio vulnificus isolates revealed biotype 3 evolutionary relationships.Genome-wide SNP-genotyping array to study the evolution of the human pathogen Vibrio vulnificus biotype 3.Quantitative and qualitative analyses of the bacterial microbiota of tilapia (Oreochromis niloticus) cultured in earthen ponds in the Philippines.Genotypic Diversity and Population Structure of Vibrio vulnificus Strains Isolated in Taiwan and Korea as Determined by Multilocus Sequence Typing.Vibrio Vulnificus Necrotizing Fasciitis Associated with Acupuncture.Draft Genome Sequence of Israeli Outbreak-Associated Vibrio vulnificus Biotype 3 Clinical Isolate BAA87 Soft tissue infections caused by marine bacterial pathogens: epidemiology, diagnosis, and management.Variable Virulence of Biotype 3 Vibrio vulnificus due to MARTX Toxin Effector Domain Composition.MARTX effector cross kingdom activation by Golgi-associated ADP-ribosylation factors.Vibrio Pathogens: A Public Health Concern in Rural Water Resources in Sub-Saharan Africa.Epidemiologic study of Vibrio vulnificus infections by using variable number tandem repeats.Occurrence of Virulence Genes Associated with Human Pathogenic Vibrios Isolated from Two Commercial Dusky Kob (Argyrosmus japonicus) Farms and Kareiga Estuary in the Eastern Cape Province, South Africa.

P2860

Q26799804-69604212-0D36-42EC-BB3D-DAF40E2BA266 Q30774185-7B064015-E67B-4D36-A231-6F1B79F659CC Q33741437-12E4BBF4-C64D-4A20-B496-C7560AA54291 Q34969864-729005A7-09DC-4987-A963-FC46152B7331 Q35530829-7E12B1E5-8FAA-4FFC-86CF-E2556FF3BE41 Q35537265-38D9F2F6-F880-4442-BE15-9A0B42DAC34F Q35850138-457C0B44-88DD-4E54-BFE8-FC612CB13871 Q36123045-C1260626-40B2-4FB9-87B4-54FA999B420B Q37653441-652E438B-FBDC-4023-8A5B-C0DBE0C745D0 Q37904804-1CD97E9D-D182-407D-874B-68FFC200A352 Q40080611-B2010EC0-C9B7-4383-8BE8-F0EFECF78DCA Q40094461-B0B9F448-E181-4270-A102-B3134155C978 Q41921695-993F61AC-1B68-45F4-A4BC-B639F4C33D2B Q42924095-0C64EF02-CDEB-43D9-A8E1-8917B66317A0 Q47103423-5CAD3B05-7EDE-4D0A-99B0-CA08F3AA5536

P2860

Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel.

http://www.wikidata.org/entity/Q37080812

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel.

@en

Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel.

@nl

type

label

Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel.

@en

Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel.

@nl

prefLabel

Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel.

@en

Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel.

@nl

P1433

Q37080812-26771BDC-3CA0-4F6C-8AAD-511FE5A95CEA

P1476

Q37080812-E8386E81-F455-4573-BD0D-E748C4207C78

P2093

Q37080812-01196B3F-B819-4760-A5C8-D41F75823FF3

Q37080812-0461874A-8782-4130-9842-55AF025B52B2

Q37080812-080C31AB-7C5D-4040-A502-5FFA2E2D60D3

Q37080812-1C52A28D-F94D-4735-AAD5-0756136B0B89

Q37080812-3C8A4E6C-115F-4F00-92C1-641E18D047BC

Q37080812-55BC7435-FF6A-4A54-86D4-8359DE9ADFD7

Q37080812-5D9F96FA-67FB-40C5-BD0F-C87E9955EEEE

Q37080812-8A621224-470A-46C6-B747-9B54678E42E3

Q37080812-B412899A-C3AE-439F-8872-0DC953533C90

Q37080812-FE8E0294-4D0E-498B-8AF4-908C260669ED

P2860

Q37080812-0773E0D9-111B-426C-B07A-F37DED360DD0

Q37080812-0D8ED442-BDE1-4145-BDA6-D7E5D143E1A8

Q37080812-108D5912-C54D-4DD6-96CF-F74FD74B4029

Q37080812-121EB276-3393-4C8F-BFA6-9A796A7FF51D

Q37080812-16D7F377-183B-4455-8E8E-184E9501FA23

Q37080812-206EE336-C706-4FEE-8E65-E3A113348BD4

Q37080812-216008FE-E9B4-4E17-A731-704017F38798

Q37080812-2D355280-0C83-4BEC-A75F-81864FF2C5D1

Q37080812-34B910FA-F501-4996-ADCD-6F56C6F2C1C1

Q37080812-4373EA66-5BEC-44B6-962A-2FDD8A521247

P304

Q37080812-4B9FAC67-CDB1-4124-BCD3-B06D4E1077FB

P31

Q37080812-231B4D76-485A-46A1-8FFC-7F0231850689

P356

Q37080812-E1265EDC-6EBB-4D0C-9BB7-9672E5A0758C

P433

Q37080812-E3289D3B-7F55-40CC-9A06-3D62D8A6BFE1

P478

Q37080812-D0938C3E-00B1-4AFE-81F5-B82E569DF95D

P577

Q37080812-5D2BC536-7572-4E15-B3E4-EE9A0F066744

P5875

Q37080812-C0E59998-52E4-4276-AF97-9D08D56293DB

P698

Q37080812-7074203B-77EE-4DAD-A66E-7FC7CD036055

P921

Q37080812-BAB0FA0F-5DF3-4028-8D52-D568996066CD

P932

Q37080812-3E861C79-7E77-472D-AC58-0DBFED6239D2

P356

P1433

Emerging Infectious Diseases

P1476

Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel.

@en

P2093

Chantal Sadik

http://www.w3.org/2001/XMLSchema#string

Cheryl Bopp

http://www.w3.org/2001/XMLSchema#string

June Kopelowitz

http://www.w3.org/2001/XMLSchema#string

Larisa Lerner

http://www.w3.org/2001/XMLSchema#string

Lea Valinsky

http://www.w3.org/2001/XMLSchema#string

Michele Parsons

http://www.w3.org/2001/XMLSchema#string

Miriam Weinberger

http://www.w3.org/2001/XMLSchema#string

Ronit Zaidenstein

http://www.w3.org/2001/XMLSchema#string

Ruth Yishai

http://www.w3.org/2001/XMLSchema#string

Vered Agmon

http://www.w3.org/2001/XMLSchema#string

P2860

Establishment of a universal size standard strain for use with the PulseNet standardized pulsed-field gel electrophoresis protocols: converting the national databases to the new size standard

Essential role for estrogen in protection against Vibrio vulnificus-induced endotoxic shock

Cholera and other types of vibriosis: a story of human pandemics and oysters on the half shell.

Identification of the emerging pathogen Vibrio vulnificus biotype 3 by commercially available phenotypic methods.

Climate change and the emergence of Vibrio vulnificus disease in Israel.

Comparison of direct genome restriction enzyme analysis and pulsed-field gel electrophoresis for typing of Vibrio vulnificus and their correspondence with multilocus sequence typing data.

Epidemiology and pathogenesis of Vibrio vulnificus.

Prognostic factors and antibiotics in Vibrio vulnificus septicemia.

Population genetics of Vibrio vulnificus: identification of two divisions and a distinct eel-pathogenic clone.

In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents.

P304

1875-1882

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3201/EID1412.080499

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23559459

http://www.w3.org/2001/XMLSchema#string

P698

19046510

http://www.w3.org/2001/XMLSchema#string

P921

P932

2634625

http://www.w3.org/2001/XMLSchema#string